Vanogut125 mg

Vancomycin hydrochloride is a glycopeptide antibiotic with two distinct forms of use depending on the route:

Intravenous Use

• Serious infections caused by susceptible gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), when other antibiotics are ineffective or cannot be used, including bloodstream infections, endocarditis, bone and joint infections, skin and soft tissue infections, and pneumonia

Oral Use

• Clostridioides difficile-associated diarrhoea and colitis (pseudomembranous colitis) - oral vancomycin is not absorbed into the bloodstream and acts locally within the gut for this specific indication

Oral vancomycin is not effective for other (systemic) infections, since it is not absorbed from the gastrointestinal tract; IV vancomycin, conversely, does not reach effective concentrations in the gut lumen and is not used to treat C. difficile colitis.

Contains Vanogut 125 mg as the active ingredient, available as a powder for injection (for IV infusion, commonly in 500 mg and 1 g vials) and as oral capsules or an oral solution (for C. difficile colitis).

Vancomycin is a glycopeptide antibiotic used intravenously for serious infections caused by resistant gram-positive bacteria, including MRSA, and used orally, in a completely different role, for a specific type of antibiotic-associated colitis caused by Clostridioides difficile. Because IV vancomycin has a narrow safety margin regarding kidney and hearing toxicity, and because rapid infusion can cause a distinctive reaction called "vancomycin infusion reaction" (previously called red man syndrome), it requires careful, monitored administration and, for many patients, blood level monitoring to guide dosing.

Therapeutic Class: Antibiotic (Glycopeptide)

IV vancomycin is eliminated almost entirely by the kidneys, and its half-life is significantly prolonged in renal impairment, requiring dose or interval adjustment. Because vancomycin's antibacterial activity against certain organisms correlates with the total drug exposure over time relative to the bacteria's susceptibility (AUC/MIC), current best practice increasingly uses this measure, rather than trough levels alone, to individualize dosing, though trough-level-based monitoring (commonly targeting 10-20 mg/L for many infections) remains widely used. Oral vancomycin is poorly absorbed from the gastrointestinal tract, which is intentional for its use in C. difficile colitis, keeping the drug concentrated in the gut where the infection is located.

• IV vancomycin must be given as a slow infusion - typically over at least 60 minutes for a standard dose (with longer infusion times for higher doses), given the risk of infusion-related reactions with rapid administration; never given as a rapid IV push
• Administered only by trained healthcare professionals, with the infusion site monitored for irritation
• Oral vancomycin capsules or solution are taken by mouth, at evenly spaced intervals, and are not effective for systemic infections since they are not significantly absorbed
• Complete the full prescribed course, even if symptoms improve before the course is finished

The following should be assessed by a healthcare professional before combining with vancomycin, particularly the IV form:

• Aminoglycosides (such as gentamicin) and other nephrotoxic or ototoxic drugs: combined use significantly increases the risk of kidney and hearing toxicity; requires careful monitoring if used together.
• Piperacillin-tazobactam: combined use with vancomycin has been associated with an increased risk of acute kidney injury compared to either agent alone; monitor renal function closely if combined.
• Loop diuretics (such as furosemide): may increase the risk of nephrotoxicity when combined with vancomycin, particularly in intensive care settings.
• Anaesthetic agents: combining with vancomycin during anaesthesia has been associated with erythema and histamine-like flushing reactions.
• Other drugs affecting neuromuscular transmission: use with caution given theoretical additive effects.

Common side effects (IV use)

• Vancomycin infusion reaction (red man syndrome): flushing, itching, and rash of the upper body, sometimes with low blood pressure, typically occurring with rapid infusion - preventable by infusing more slowly and, for future doses, with antihistamine premedication
• Injection site pain or phlebitis (vein irritation)
• Nausea

Common side effects (oral use)

• Nausea, abdominal pain
• Generally well tolerated given minimal systemic absorption

Serious side effects (require prompt medical attention) - mainly with IV use

• Nephrotoxicity: reduced urine output, swelling - risk increases with higher trough levels, prolonged therapy, and combination with other nephrotoxic drugs; kidney function is monitored throughout treatment.
• Ototoxicity: ringing in the ears, hearing loss, dizziness - historically associated with high serum levels (80-100 mg/L), though reported occasionally at lower levels; more likely with prolonged therapy (over 10 days) or pre-existing hearing impairment.
• Severe infusion reactions: significant hypotension, wheezing, difficulty breathing, or anaphylactoid reactions with rapid infusion.
• Reversible neutropenia, typically starting after a week or more of therapy or with cumulative doses above about 25 g.
• Severe skin reactions (rare): blistering, peeling skin.

Pregnancy

Vancomycin has been used in pregnancy for serious infections, including MRSA, when clinically necessary; use should be guided by the treating physician, weighing the benefit of treating a serious infection against any potential risk, given limited controlled human data.

Breastfeeding

Vancomycin passes into breast milk in small amounts; oral absorption by the infant is expected to be minimal, given vancomycin's own poor gastrointestinal absorption. Use should be discussed with a healthcare professional.

• Infuse slowly: IV vancomycin must be given over at least 60 minutes (longer for higher doses) to reduce the risk of infusion reactions; never give as a rapid injection.
• Nephrotoxicity and ototoxicity monitoring: particularly important with prolonged therapy (beyond about 7-10 days), pre-existing renal impairment, concurrent nephrotoxic or ototoxic drugs, or in elderly patients; monitor renal function and, where feasible, hearing during extended courses.
• Blood level monitoring: guides dosing for many patients, particularly those on prolonged IV therapy or with changing kidney function.
• Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi.
• Oral vancomycin should be reserved for C. difficile-associated disease and is not effective for other infections given minimal systemic absorption.

Overdose or excessive drug accumulation (particularly in renal impairment) increases the risk of nephrotoxicity, ototoxicity, and, with very high levels, more severe systemic toxicity. Suspected significant overdose requires prompt medical evaluation, including monitoring of blood levels, kidney function, and hearing; haemodialysis using high-flux membranes may help reduce vancomycin levels in cases of significant overdose or accumulation with renal failure, under specialist guidance.

Store unreconstituted injectable powder at controlled room temperature, protected from light, as directed on the product label. Reconstituted and diluted IV solutions should be used according to the manufacturer's specific stability instructions; discard any unused portion after this period. Store oral capsules or solution at room temperature as directed.

• Renal impairment: Requires significant dose or interval adjustment, given vancomycin's near-total renal elimination; blood level monitoring is particularly important in this population.
• Elderly: Often have reduced renal function even with normal-appearing serum creatinine; monitor closely and adjust dosing accordingly.
• Neonates and infants: Dosing is weight- and age-based, with close monitoring of renal function and blood levels, given developing kidney function in this population.
• Pre-existing hearing impairment: Use with particular caution during prolonged therapy, given the risk that vancomycin-related ototoxicity may be masked or confounded by existing hearing loss.

Duration depends on the specific infection - IV therapy for serious systemic infections may last 1-6 weeks or longer depending on the site and severity (such as endocarditis or bone infections requiring extended courses); oral therapy for C. difficile-associated colitis is typically a 10-day course for an initial episode, with longer or tapered regimens sometimes used for recurrent disease, as directed by the treating physician.

The IV injectable powder must be reconstituted with sterile water for injection per the specific product's instructions, then further diluted in an appropriate IV fluid before infusion. Reconstituted and diluted solutions should be used according to the manufacturer's stability data; discard any unused portion after this period.

Drug Class: Glycopeptide antibacterial

Vancomycin works by binding to a specific building block used in bacterial cell wall construction, blocking the cell wall synthesis process in susceptible gram-positive bacteria. This weakens the bacterial cell wall, causing the bacteria to become unstable and die (a bactericidal effect for most susceptible organisms). Because gram-negative bacteria have a different cell wall structure that vancomycin cannot penetrate, it is not effective against them.

Vancomycin is used in infants and children, including neonates, for both IV (serious gram-positive infections) and oral (C. difficile colitis) indications, with dosing based on age and weight, and close monitoring of renal function and blood levels given developing kidney function in this population, particularly in neonates and young infants.